Product Strategy
ViRexx's business strategy is to develop and commercialize therapeutic products originating from the Company's AIT™, Chimigen™ & T-ACT™ platform technologies in a timely and effective manner. The Company will realize value by focusing on commercializing unique, patent-protected and patent-pending products through pharmaceutical company partnerships and alliances. In order to build value for strategic partnering, ViRexx will aggressively pursue regulatory approval of products by conducting additional research and directing pre-clinical and Phase I and II clinical trials.
The Company's initial focus and commercialization efforts will be on the lead OvaRex® MAb, BrevaRex®, Occlusin™ Injection, HepaVaxx B and HepaVaxx C products. Partnerships with major pharmaceutical companies will be established for the final phase of human testing, worldwide regulatory approvals, manufacturing scale-up, and marketing. In addition, ViRexx intends to leverage the AIT™, Chimigen™ and T-ACT™ technology platforms to accelerate the development of products for other indications.
The Company intends to maintain a core staff sufficient to strengthen
and enhance its intellectual property position. Selected preclinical
work will be outsourced to other scientific organizations and clinical
trials will be conducted through contractual agreements with reputable
Contract Research Organizations.